Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...

Many Wall Street analysts think Novo Nordisk will make a solid rebound over the next 12 months. The company may have ...

Aide to RFK Jr. says White House is pushing for global price parity on GLP-1 drugs for weight loss. Read more here.

The drug is set to be available on the NHS for weight loss soon, but one expert has flagged some potential risks that come with it.

CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...

We recently published a list of 12 Best Major Stocks to Buy According to Billionaires. In this article, we are going to take ...